11 November 2021 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES: The influence of preoperative left ventricular size in outcomes following centrifugal-flow left ventricular assist device (LVAD) implantation has not been well characterized. METHODS: A cohort of 313 patients who received a centrifugal-flow LVAD at a single institution was analysed. Using a maximally selected log-rank statistic, we investigated whether a left ventricular end-diastolic dimension (LVEDD) cut-off point was associated with worse outcomes. The cohort was then divided in 2 groups based on the LVEDD cut-off point. RESULTS: An LVEDD cut-off point of 59 mm was found to predict worse survival. Smaller LVEDD patients (≤59 mm, N = 52) were older and more likely to have a history of coronary artery disease compared those with a larger LVEDD (>59 mm, N = 261). Smaller LVEDD patients had lower survival compared to larger LVEDD patients (71% vs 85% at 1 year and 58% vs 80% at 2 years, P = 0.003). The need for temporary right ventricular mechanical support was significantly higher in the smaller LVEDD cohort (11.5% vs 1.9%, P = 0.002). Pump flows at time of discharge were lower in the smaller LVEDD group (3.8 vs 4.2 l/min, P = 0.005), who also had a higher incidence of late right ventricular failure (23% vs 12%, P = 0.02), higher rates of gastrointestinal bleeding (0.416 vs 0.256 events per patient-year, P = 0.025) and higher readmissions secondary to low flow alarms (0.429 vs 0.240 events per patient-year, P = 0.007). Multivariable analysis demonstrated that smaller LVEDD, older age, high BUN and high bilirubin levels were independent predictors of worse survival. CONCLUSIONS: In patients receiving a centrifugal-flow LVAD, smaller preoperative LVEDD (≤59 mm) was associated with lower survival and higher incidence of adverse outcomes.
24 January 2020 in Catheterization and Cardiovascular Interventions
21 April 2021 in ASAIO Journal
The impact of preoperative end-diastolic left ventricular dimension (preLVEDD) on long-term outcomes with centrifugal continuous-flow left ventricular assist device (CF-LVAD) is not well established. Accordingly, we performed an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry to study this relationship. All patients with centrifugal CF-LVAD in the INTERMACS registry from June 2006 to December 2017 were screened. The final study group consisted of 3,304 patients. After a median follow-up of 9.0 months (interquartile range [IQR], 4.2–18.8 months), 2,596 (79%) patients were alive. After adjusting for significant covariates, increased preLVEDD was associated with lower mortality (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.84–0.98; p = 0.01), stroke (HR, 0.85; 95% CI, 0.77–0.93; p < 0.001), and gastrointestinal bleeding (HR, 0.88; 95% CI, 0.80–0.97; p = 0.01), although there were more arrhythmias (HR, 1.14; 95% CI, 1.05–1.24; p = 0.003). Our study suggests that preLVEDD is an independent predictor of mortality and adverse events in patients treated with centrifugal CF-LVAD. preLVEDD should be considered an important preimplant variable for risk stratification when considering a CF-LVAD.
1 August 2020 in HeartRhythm Case Reports
14 January 2026 in Heart, Lung and Circulation
Following guideline-directed medical therapy (GDMT) is crucial for managing acute heart failure (AHF). Australia has poor adherence to GDMT with only a small proportion of eligible patients receiving optimal HF therapy. Therefore, there is a real need for unified recommendations to optimise GDMT for patients hospitalised with AHF in Australia. Using a modified DELPHI method, an expert panel of nine Australian clinicians with expertise in HF management convened to develop consensus statements aimed at guiding healthcare professionals in Australia on optimising GDMT. This document outlines a strategy for ensuring patients are started on GDMT while they are in hospital and that GDMT is optimised to maximum tolerated doses rapidly after discharge. This is especially critical because rapid optimisation of heart failure (HF) therapies and close follow-up in the early period after HF hospitalisation has been found to decrease all-cause mortality and reduce the risk of HF readmission. These consensus statements provide a practical framework to help Australian healthcare professionals in optimising GDMT for their patients. This framework is designed to enhance the current AHF guidelines. The consensus statements support the ongoing priority of optimising GDMT for AHF management aiming to ensure that eligible patients receive the optimal therapy for their clinical presentation.
10 March 2020 in Catheterization and Cardiovascular Interventions